1 Result(s)

Article

The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel mult...

Ina Patties, Sonja Kallendrusch, Lisa Böhme… in Journal of Experimental & Clinical Cancer … (2019)